NCT07537426 The Efficacy of Intradermal Acupuncture for Ocular Surface Diseases After Intractable Facial Paralysis
| NCT ID | NCT07537426 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Zhejiang Chinese Medical University |
| Condition | Facial Paralysis, Peripheral |
| Study Type | INTERVENTIONAL |
| Enrollment | 78 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 78 participants in total. It began in 2026-04-01 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to explore the clinical efficacy of intradermal acupuncture in the treatment of ocular surface diseases after Intractable Facial Paralysis, and to seek effective and convenient treatment for ocular surface diseases after intractable peripheral facial paralysis. The main question it aims to answer is ： Will the intradermal acupuncture intervention effectively reduce the OSDI score ? The researchers compared the intradermal acupuncture with the placebo-needle to observe whether the intradermal acupuncture could better improve the symptoms.
Eligibility Criteria
Inclusion Criteria: * 1.Male or female patients aged 18-65 years. * 2.Meets diagnostic criteria for intractable peripheral facial paralysis, with disease duration from 1 month to 1 year. FNGS 2.0 ≥15 points; ENoG shows the ratio of CMAP amplitude≤ 20%. * 3.At least one subjective ocular symptom (dryness, foreign body sensation, burning, fatigue, redness, fluctuating vision) and OSDI scores between 30 and 80. * 4.Voluntarily provides written informed consent and can comply with treatment and follow-up. Exclusion Criteria: * 1.Other ocular diseases (glaucoma, keratitis, retinopathy, acute inflammation of conjunctiva, sclera, cornea). * 2\. Intraocular surgery or laser therapy within the past 90 days. * 3.Use of systemic or topical antibiotics or tear-affecting drugs within 3 weeks; dry eye medications within 2 weeks. * 4.Lacrimal passage obstruction, dacryocystitis, punctal occlusion, or neurological impairment preventing full eyelid closure. * 5.Coagulation disorders, open wounds, or local infection at intervention sites. * 6.Allergy to press-needle materials (stainless steel, adhesive tape). * 7.Pregnancy or lactation. * 8.Severe cardiac, hepatic, renal, psychiatric disorders, or malignant tumors. * 9.Participation in another clinical trial within the past month.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07537426 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Facial Paralysis, Peripheral. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07537426 currently recruiting?
Yes, NCT07537426 is actively recruiting participants. Contact the research team at 20103034@zcmu.edu.cn for enrollment information.
Where is the NCT07537426 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07537426 clinical trial?
NCT07537426 is sponsored by The First Affiliated Hospital of Zhejiang Chinese Medical University. The trial plans to enroll 78 participants.